scholarly journals An evaluation of people’s knowledge of adult vaccination information level and attitudes during the pandemic Era

2021 ◽  
Vol 67 (11) ◽  
pp. 1595-1599
Author(s):  
Neşe Kıskaç ◽  
Muharrem Kiskaç ◽  
Abdüsselam Şekerci ◽  
Mehmet Zorlu
Keyword(s):  
Information Level ◽  
Adult Vaccination

Understanding what people think and feel about adult vaccinations and the associated barriers in Greece: Development and validation of the attitude towards adult vaccination (ATAVAC) scale

2021 ◽  
Vol 29 (3) ◽  
pp. 818-828
Author(s):  
Zoi Tsimtsiou ◽  
Ioanna Tsiligianni ◽  
Anastasia Papaioannou ◽  
Dimitrios Gougourelas ◽  
Konstantinos Kolokas ◽  
...  
Keyword(s):  
Adult Vaccination ◽  
Development And Validation

scholarly journals 87. Impact of State of Residence on Adult Vaccination Uptake: A Multilevel Modeling Approach

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S175-S175
Author(s):  
Shannon Hunter ◽  
Diana Garbinsky ◽  
Elizabeth M La ◽  
Sara Poston ◽  
Cosmina Hogea
Keyword(s):  
Multilevel Modeling ◽  
Vaccination Coverage ◽  
Multilevel Models ◽  
State Level ◽  
Childhood Vaccination ◽  
Material Support ◽  
Adult Vaccination ◽  
Direct Compensation ◽  
Cluster Variation ◽  
Coverage Rates

Abstract Background Previous studies on adult vaccination coverage found inter-state variability that persists after adjusting for individual demographic factors. Assessing the impact of state-level factors may help improve uptake strategies. This study aimed to: • Update previous estimates of state-level, model-adjusted coverage rates for influenza; pneumococcal; tetanus, diphtheria, and acellular pertussis (Tdap); and herpes zoster (HZ) vaccines (individually and in compliance with all age-appropriate recommended vaccinations) • Evaluate effects of individual and state-level factors on adult vaccination coverage using a multilevel modeling framework. Methods Behavioral Risk Factor Surveillance System (BRFSS) survey data (2015–2017) were retrospectively analyzed. Multivariable logistic regression models estimated state vaccination coverage and compliance using predicted marginal proportions. BRFSS data were then combined with external state-level data to estimate multilevel models evaluating effects of state-level factors on coverage. Weighted odds ratios and measures of cluster variation were estimated. Results Adult vaccination coverage and compliance varied by state, even after adjusting for individual characteristics, with coverage ranging as follows: • Influenza (2017): 35.1–48.1% • Pneumococcal (2017): 68.2–80.8% • Tdap (2016): 21.9–46.5% • HZ (2017): 30.5–50.9% Few state-level variables were retained in final multilevel models, and measures of cluster variation suggested substantial residual variation unexplained by individual and state-level variables. Key state-level variables positively associated with vaccination included health insurance coverage rates (influenza/HZ), pharmacists’ vaccination authority (HZ), presence of childhood vaccination exemptions (pneumococcal/Tdap), and adult immunization information system participation (Tdap/HZ). Conclusion Adult vaccination coverage and compliance continue to show substantial variation by state even after adjusting for individual and state-level characteristics associated with vaccination. Further research is needed to assess additional state or local factors impacting vaccination disparities. Funding GlaxoSmithKline Biologicals SA (study identifier: HO-18-19794) Disclosures Shannon Hunter, MS, GSK (Other Financial or Material Support, Ms. Hunter is an employee of RTI Health Solutions, who received consultancy fees from GSK for conduct of the study. Ms. Hunter received no direct compensation from the Sponsor.) Diana Garbinsky, MS, GSK (Other Financial or Material Support, The study was conducted by RTI Health Solutions, which received consultancy fees from GSK. I am a salaried employee at RTI Health Solutions and received no direct compensation from GSK for the conduct of this study..) Elizabeth M. La, PhD, RTI Health Solutions (Employee) Sara Poston, PharmD, The GlaxoSmithKline group of companies (Employee, Shareholder) Cosmina Hogea, PhD, GlaxoSmithKline (Employee, Shareholder)

scholarly journals PIN54 THE COST-EFFECTIVENESS OF THE NEW PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PCVI3) FOR CHILDHOOD AND ADULT VACCINATION IN THE UK

2009 ◽  
Vol 12 (7) ◽  
pp. A427 ◽  
Author(s):  
R Patel ◽  
B Stoykova ◽  
AC Lloyd ◽  
J Willingham ◽  
R Hollingsworth
Keyword(s):  
Cost Effectiveness ◽  
Conjugate Vaccine ◽  
Adult Vaccination ◽  
The Uk ◽  
The Cost

scholarly journals Persistence of Pneumococcal Serotype 3 in Adult Pneumococcal Disease in Hong Kong

Vaccines ◽  
2021 ◽  
Vol 9 (7) ◽  
pp. 756
Author(s):  
Reema Subramanian ◽  
Veranja Liyanapathirana ◽  
Nilakshi Barua ◽  
Rui Sun ◽  
Maggie Haitian Wang ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Pneumococcal Disease ◽  
Disease Burden ◽  
Patient Characteristics ◽  
Adult Vaccination ◽  
Pneumococcal Serotype ◽  
Pneumococcal Immunisation ◽  
Microbroth Dilution ◽  
Over Time

The epidemiology of hospitalised pneumococcal disease in adults following the introduction of universal childhood pneumococcal immunisation in 2009 was assessed. Culture-confirmed Streptococcus pneumoniae (SP) from adults hospitalised between 2009 to 2017 were examined. The cases were categorised into invasive pneumococcal disease (IPD) and pneumonia (bacteraemic, non-bacteraemic, and that associated with other lung conditions). The isolates were serotyped and antimicrobial susceptibilities were determined by microbroth dilution. Patient characteristics, comorbidities, and outcomes were analysed. Seven hundred and seventy-four patients (mean age, 67.7 years, SD ± 15.6) were identified, and IPD was diagnosed in 110 (14.2%). The most prevalent serotype, 19F, was replaced by serotype 3 over time. Penicillin and cefotaxime non-susceptibilities were high at 54.1% and 39.5% (meningitis breakpoints), 19.9% and 25.5% (non-meningitis breakpoints), respectively. The overall 30-day mortality rate was 7.8% and 20.4% for IPD. Age ≥ 75 years (OR:4.6, CI:1.3–17.0, p < 0.02), presence of any complications (OR:4.1, CI:1.02–16.3, p < 0.05), pleural effusion (OR:6.7, CI:1.2–39.4, p < 0.03) and intensive care unit (ICU) admission (OR:9.0, CI:1.3–63.4, p < 0.03) were independent predictors of 30-day mortality. Pneumococcal disease by PCV 13 covered serotypes; in particular, 19F and 3 are still prominent in adults. Strengthening targeted adult vaccination may be necessary in order to reduce disease burden.

Sign in / Sign up

Export Citation Format

Share Document